US restaurants are reducing meal portions and prices amid a dual challenge of soaring living costs and growing demand for anti-obesity medications. The Financial Times reports that diners increasingly prioritize affordability, with many opting for budget-friendly options as prescription drugs like Wegovy and Ozempic reshape consumer spending habits. This shift reflects broader economic pressures, as households allocate more income to healthcare while tightening food budgets.

The trend has intensified since 2023, when portion sizes in mid-range eateries dropped by 10-15% on average, according to industry data. Operators attribute this to dual pressures: anti-obesity drug adoption skewing demand toward cheaper meals and inflation eroding purchasing power. For example, chains like Chili’s and Applebee’s have introduced “value menus” emphasizing smaller, cheaper plates, while fast-food giants quietly adjust combo deals to offset ingredient cost hikes.

Market analysts warn this could reshape the restaurant industry’s revenue models, as declining average ticket sizes threaten profit margins. Some establishments are experimenting with “health-focused” portion controls, aligning with anti-obesity trends but risking customer dissatisfaction. Meanwhile, regulatory scrutiny is emerging, with lawmakers in New York and California proposing menu labeling reforms to address portion transparency amid health-driven consumer behavior.

Key implications include potential menu homogenization, as restaurants prioritize cost-effective ingredients over diverse offerings. Investors are closely monitoring deal values in the sector, with private equity firms signaling caution about long-term viability. The situation underscores a fragile balance between public health initiatives and economic realities in America’s dining landscape.